Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm clofarabine plus low-dose cytarabine in older untreated acute myeloid leukemia
2010-019718-25Phase 2Terminated
- Sponsor
- Fundación PETHEMA
- Start
- Jun 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine and cytarabine in acute myeloid leukemia (AML), sponsored by Fundación PETHEMA. Primary endpoint: Overall remission rate. Started Jun 2010; status: terminated.
02
Drugs
clofarabinecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2010-019718-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019718-25.